芷玄镇痛片治疗紧张型头痛的真实世界人用经验研究

庄奥林1,2,陈娟1,渠文生2,刘娜2

神经损伤与功能重建 ›› 2026, Vol. 21 ›› Issue (10) : 580-583.

PDF(951 KB)
中国科技核心期刊
美国《化学文摘》CAS数据库收录
日本科学技术振兴机构数据库收录
湖北省优秀期刊
中国知网网络首发期刊
PDF(951 KB)
神经损伤与功能重建 ›› 2026, Vol. 21 ›› Issue (10) : 580-583. DOI: 10.16780/j.cnki.sjssgncj.20261254
论著

芷玄镇痛片治疗紧张型头痛的真实世界人用经验研究

  • 庄奥林1,2,陈娟1,渠文生2,刘娜2
作者信息 +

A Real-World Human Experience Study of Zhixuan Analgesic Tablets in the Treatment of Tension-Type Headache

  • ZHUANG Aolin1,2, CHEN Juan1, QU Wensheng2, LIU Na2
Author information +
文章历史 +

摘要

目的:依据国家药监局相关指导原则,推进芷玄镇痛片的新药注册转化进程,系统总结其治疗紧张型头痛的人用经验,为新药研发与临床推广提供循证依据。方法:采用前瞻性真实世界研究设计,纳入紧张型头痛患者250例。给予芷玄镇痛片口服(4片/次,3次/日),连续干预12周。以月头痛发作天数为主要疗效指标;以有效应答率、急性止痛药物使用天数、视觉模拟量表(VAS)评分及头痛影响测评量表(HIT-6)评分为次要疗效指标;同时评估安全性。结果: 最终232例纳入意向性分析。与基线相比,第3个干预月,患者月头痛天数显著下降[(3.63±4.41)d vs.(10.76±3.59)d,P<0.05],临床有效应答率为71.55%;急性止痛药物使用天数、平均及峰值VAS评分、HIT-6评分较基线均显著降低(P<0.05)。研究全周期不良事件总发生率为7.6%(19/250),以轻度胃肠道反应(5.6%)和轻度头晕(2.21%)为主,未发生严重不良事件。结论:真实世界研究提示,芷玄镇痛片能显著减少紧张型头痛患者的头痛发作频率,减轻疼痛程度,减少急性止痛药使用并改善生活质量,且安全性良好,为其新药转化及临床推广提供了有力的人用经验证据。

Abstract

Objective: Based on relevant guidelines from the National Medical Products Administration, this study aims to advance the new drug registration process for Zhixuan Analgesic Tablets and systematically summarize its human use experience in treating tension-type headache (TTH), providing evidence-based support for new drug development and clinical promotion. Methods: A prospective real-world study design was employed, enrolling 250 TTH patients. Patients were administered oral Zhixuan Analgesic Tablets (4 tablets per dose, 3 times daily) for a continuous 12-week intervention. The primary efficacy outcome was the number of monthly headache days; secondary outcomes included response rate, acute analgesic usage days, Visual Analog Scale (VAS) scores, and Headache Impact Test-6 (HIT-6) scores. Safety was also assessed. Results: Of 250 enrolled patients, 232 completed intention-to-treat analysis. Compared with baseline, at the third month of intervention, the mean monthly headache days significantly decreased [(3.63±4.41) days vs. (10.76±3.59) days, P<0.05], with a clinical response rate of 71.55%. Secondary outcomes, including acute analgesic usage days, average/peak VAS scores, and HIT-6 scores, all showed significant reductions compared with baseline (P<0.05). The overall incidence of adverse events during the study was 7.6% (19/250), primarily mild gastrointestinal reactions (5.6%) and mild dizziness (2.21%), with no severe adverse events reported. Conclusion: Real-world evidence indicates that Zhixuan Analgesic Tablets significantly reduce headache frequency, alleviate pain intensity, decrease acute analgesic use, and improve quality of life in TTH patients. The favorable safety profile supports its potential for new drug conversion and clinical implementation.

关键词

芷玄镇痛片;紧张型头痛;真实世界研究;人用经验

Key words

Zhixuan Analgesic Tablets; tension-type headache; real-world study; human-use experience

引用本文

导出引用
庄奥林1,2,陈娟1,渠文生2,刘娜2. 芷玄镇痛片治疗紧张型头痛的真实世界人用经验研究[J]. 神经损伤与功能重建. 2026, 21(10): 580-583 https://doi.org/10.16780/j.cnki.sjssgncj.20261254
ZHUANG Aolin1,2, CHEN Juan1, QU Wensheng2, LIU Na2. A Real-World Human Experience Study of Zhixuan Analgesic Tablets in the Treatment of Tension-Type Headache[J]. Neural Injury and Functional Reconstruction. 2026, 21(10): 580-583 https://doi.org/10.16780/j.cnki.sjssgncj.20261254

基金

同济医院制剂研发转化基金(两种医院制剂治疗紧张型头痛的前瞻性人用经验及随机对照研究No. ,24-2ZJZ0802-07)

PDF(951 KB)

Accesses

Citation

Detail

段落导航
相关文章

/

〈 〉